Quantcast

Latest metastatic melanoma Stories

2010-06-07 05:00:00

KNOXVILLE, Tenn., June 7 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. Sanjiv Agarwala at the American Society of...

2010-05-12 07:58:00

INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Data from several Lilly Oncology compounds in development - a total of 13 studies - will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 4 - 8, 2010. Lilly Oncology's pipeline is one of the largest in the industry, with more than 20 molecules in development. The pipeline data include two Phase II studies evaluating the use of tasisulam (a novel anti-cancer...

2009-11-02 15:10:00

WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a...

2009-08-11 09:56:00

KNOXVILLE, Tenn., Aug. 11 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) reports on its year-to-date clinical and corporate accomplishments in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/pvct/39628/ Dear Shareholders: I am pleased to report that 2009 has already been a year of continued progress and excitement for Provectus. Our clinical trials for both PV-10 and...

2009-07-29 15:15:16

U.S. researchers say dendritic cell vaccines may lead to long-term survival for metastatic melanoma patients, the most serious form of skin cancer. The study, published in the journal Cancer Biotherapy and Radiopharmaceuticals, reported eight out of 54 metastatic melanoma patients treated experienced remarkable long-term, progression-free survival -- even though they had widely metastatic disease and/or repeated appearance of new metastases despite various therapies. The one-year and...

2009-07-28 14:57:00

NEWPORT BEACH, Calif., July 28 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies. The study entitled "Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing,...

2009-07-28 15:12:36

Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.The study entitled "Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as...

2009-06-01 07:00:00

Objective Response of Treated Lesions Observed in 60% of Subjects KNOXVILLE, Tenn., June 1 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on...

2009-05-15 11:28:00

WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 - June 2, 2009 in Orlando, FL. Senior clinical investigator, Neil N. Senzer, M.D., will present the data in an abstract...

2009-04-14 07:00:00

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year....


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.